TrialPH94B in the Treatment of Adjustment Disorder With Anxiety
Trial details
- Registry ID
- NCT04404192
- Phase
- Phase 2
VTGN
VistaGen Therapeutics, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
7Trials in this database
13Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourcePH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge
Trial details
- Registry ID
- NCT04754802
- Phase
- Phase 3
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2
Trial details
- Registry ID
- NCT05011396
- Phase
- Phase 3
Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
Trial details
- Registry ID
- NCT05030350
- Phase
- Phase 3
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
Trial details
- Registry ID
- NCT06358651
- Phase
- Phase 3
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
Trial details
- Registry ID
- NCT06615557
- Phase
- Phase 3
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
Trial details
- Registry ID
- NCT06809179
- Phase
- Phase 2
Latest recorded trial changes
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
NCT06615557 · VistaGen Therapeutics, Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
236 participants (planned)
+ After
238 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Apr 2026
+ After
21 Apr 2026
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
PH94B in the Treatment of Adjustment Disorder With Anxiety
NCT04404192 · VistaGen Therapeutics, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Hamilton Anxiety Scale
+ After
Measure: Hamilton Anxiety Scale (HAM-A) Score
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
NCT06358651 · VistaGen Therapeutics, Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
236 participants (planned)
+ After
238 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Oct 2025
+ After
31 Oct 2025
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2
NCT05011396 · VistaGen Therapeutics, Inc.
Actual enrollment increased by 87 participants
− Before
141 participants (actual)
+ After
228 participants (actual)
Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
NCT05030350 · VistaGen Therapeutics, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Adverse Events and Other Safety Measures
+ After
Measure: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)